Things are suddenly looking brighter for Cappella Medical Devices Ltd. (Galway, Ireland), a developer of next generation bifurcated coronary stents. The company is reporting that it has just received a significant amount of Series C investment to help advance the company’s Sideguard® Generation Coronary Bifurcation Stent, a two piece device designed for percutaneous coronary interventions (PCI) at ostial and bifurcation lesions.
The stent is composed of the following two components:
– side branch nitinol self-expanding drug-eluting stent, shaped to conform to the ostium, and to allow continuous drug delivery throughout the ostial zone;
– main vessel drug-eluting stent, designed to fit inside the vessel and at the same time to readjust the position of Sideguard ostium protection device against the main vessel wall
More from the device info page:
Self-expanding nitinol stent Provides optimal wall apposition and scaffolding Conforms to a wide range of angles and anatomies Opens & protects the side branch, eliminating wire jailing “No gap” sequential T-stenting approach No stent foreshortening Unique balloon-catheter delivery system for nitinol stents
Enhanced deliverability & trackability
- Delivered over 0.14” guidewire
- Low-profile <3.1Fr catheter
- Single catheter design avoids wire braiding/wrappingPrecise deployment at the ostium
- Custom split-sheath technology
- Eliminates stent jumping
Video demonstrating the placement of the device:
Product page: Sideguard® – The Next Generation Coronary Bifurcation Stent
Press release: Cappella Inc. Secures $17.3 Million Series C Investment…
